The effect of intravitreal bevacizumab (avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration

Ehud Rechtman, Ingeborg Stalmans, Joseph Glovinsky, Christophe Breusegem, Joseph Moisseiev, Joachim van Calster, Alon Harris

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse amplitude (OPA). Methods: This was a two center prospective study (Sheba Medical Center, Israel, and University Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. Pearson correlation was used to evaluate the influence of various measured parameters on DCT-OPA. Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). A good correlation was found throughout the study between the DCT-intraocular pressure (IOP) and Goldmann IOP and between DCT-IOP and DCT-OPA. No change in OPA of bevacizumabtreated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between visits 1 and 3). No correlations were found between DCT-OPA and age, heart rate, systemic blood pressure, axial length, keratometry readings, and central corneal thickness. Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the safety profile of bevacizumab in AMD treatment.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalClinical Ophthalmology
Volume5
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Macular Degeneration
Intraocular Pressure
Hemodynamics
Bevacizumab
Belgium
Israel
Reading
Heart Rate
Prospective Studies
Blood Pressure
Safety
Injections

Keywords

  • Bevacizumab
  • Blood flow
  • Choroid
  • Macular degeneration
  • Ocular pulse amplitude

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The effect of intravitreal bevacizumab (avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration. / Rechtman, Ehud; Stalmans, Ingeborg; Glovinsky, Joseph; Breusegem, Christophe; Moisseiev, Joseph; van Calster, Joachim; Harris, Alon.

In: Clinical Ophthalmology, Vol. 5, No. 1, 2011, p. 37-44.

Research output: Contribution to journalArticle

Rechtman, Ehud ; Stalmans, Ingeborg ; Glovinsky, Joseph ; Breusegem, Christophe ; Moisseiev, Joseph ; van Calster, Joachim ; Harris, Alon. / The effect of intravitreal bevacizumab (avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration. In: Clinical Ophthalmology. 2011 ; Vol. 5, No. 1. pp. 37-44.
@article{16b4f015c7b849a69e6150dd50fadaec,
title = "The effect of intravitreal bevacizumab (avastin{\circledR}) on ocular pulse amplitude in neovascular age-related macular degeneration",
abstract = "Purpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse amplitude (OPA). Methods: This was a two center prospective study (Sheba Medical Center, Israel, and University Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. Pearson correlation was used to evaluate the influence of various measured parameters on DCT-OPA. Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). A good correlation was found throughout the study between the DCT-intraocular pressure (IOP) and Goldmann IOP and between DCT-IOP and DCT-OPA. No change in OPA of bevacizumabtreated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between visits 1 and 3). No correlations were found between DCT-OPA and age, heart rate, systemic blood pressure, axial length, keratometry readings, and central corneal thickness. Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the safety profile of bevacizumab in AMD treatment.",
keywords = "Bevacizumab, Blood flow, Choroid, Macular degeneration, Ocular pulse amplitude",
author = "Ehud Rechtman and Ingeborg Stalmans and Joseph Glovinsky and Christophe Breusegem and Joseph Moisseiev and {van Calster}, Joachim and Alon Harris",
year = "2011",
doi = "10.2147/OPTH.S15810",
language = "English",
volume = "5",
pages = "37--44",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - The effect of intravitreal bevacizumab (avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration

AU - Rechtman, Ehud

AU - Stalmans, Ingeborg

AU - Glovinsky, Joseph

AU - Breusegem, Christophe

AU - Moisseiev, Joseph

AU - van Calster, Joachim

AU - Harris, Alon

PY - 2011

Y1 - 2011

N2 - Purpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse amplitude (OPA). Methods: This was a two center prospective study (Sheba Medical Center, Israel, and University Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. Pearson correlation was used to evaluate the influence of various measured parameters on DCT-OPA. Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). A good correlation was found throughout the study between the DCT-intraocular pressure (IOP) and Goldmann IOP and between DCT-IOP and DCT-OPA. No change in OPA of bevacizumabtreated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between visits 1 and 3). No correlations were found between DCT-OPA and age, heart rate, systemic blood pressure, axial length, keratometry readings, and central corneal thickness. Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the safety profile of bevacizumab in AMD treatment.

AB - Purpose: To evaluate the effect of intravitreal (IVT) bevacizumab in neovascular age-related macular degeneration (AMD) on global choroidal hemodynamics, as measured by ocular pulse amplitude (OPA). Methods: This was a two center prospective study (Sheba Medical Center, Israel, and University Hospitals Leuven, Belgium). AMD patients who required IVT bevacizumab (1.25 mg/0.05 mL; first or repeated) were examined three times: at days 0 (prior to injection), 7 (±3), and 28 (±7) postinjection. At each visit, OPAs of both eyes were measured using the Pascal dynamic contour tonometer (DCT). A paired t-test between preoperative and postoperative OPA was conducted. Pearson correlation was used to evaluate the influence of various measured parameters on DCT-OPA. Results: A total of 38 neovascular AMD patients were recruited, and 30 patients were included in the final analysis (18 females and 12 males; age 78.8 ± 5.82 years [mean ± standard deviation]). A good correlation was found throughout the study between the DCT-intraocular pressure (IOP) and Goldmann IOP and between DCT-IOP and DCT-OPA. No change in OPA of bevacizumabtreated eyes was found between the visits (2.24 ± 0.73, 2.2 ± 0.86, and 2.23 ± 0.73 mm Hg at visits 1, 2, and 3, respectively; paired t-test: P = 0.77 between visits 1 and 2, P = 0.98 between visits 1 and 3). No correlations were found between DCT-OPA and age, heart rate, systemic blood pressure, axial length, keratometry readings, and central corneal thickness. Conclusions: OPA, an indirect measure of global choroidal hemodynamics, remains unchanged following IVT off-label bevacizumab. This finding adds to the growing evidence regarding the safety profile of bevacizumab in AMD treatment.

KW - Bevacizumab

KW - Blood flow

KW - Choroid

KW - Macular degeneration

KW - Ocular pulse amplitude

UR - http://www.scopus.com/inward/record.url?scp=79251551028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251551028&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S15810

DO - 10.2147/OPTH.S15810

M3 - Article

VL - 5

SP - 37

EP - 44

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

IS - 1

ER -